IL17A and colitis: In a murine model of experimental colitis, Guchangzhixie capsule could inhibit experimental colitis progression including alleviating the severity of fecal blood and albumin, shortening colon length, relieving the epithelial structural collapse, and reversing the levels of IL-17 and CXCL1 in mouse serum by hampering macrophage infiltration and suppressing its transition to M1 macrophage polarization (Yan J. et al., 2021).